Antitumor effect of locally produced CD95 ligand

被引:0
|
作者
Ken-Ichiro Seino
Nobuhiko Kayagaki
Ko Okumura
Hideo Yagita
机构
[1] Juntendo University School of Medicine,Department of Immunology
[2] University ofTsukuba School of Medicine,Department of Surgery
[3] Tsukuba Science City,undefined
[4] CREST,undefined
[5] Japan Science and Technology Corporation (JST),undefined
来源
Nature Medicine | 1997年 / 3卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Activation of the cell-surface antigen CD95 induces apoptosis of CD95-bearing tumor cells. In this study, we investigated the antitumor effect of locally produced CD95 ligand (CD95L) on CD95-negative tumor cells in vivo. Introduction of CD95L cDNA into murine tumor cells did not affect growth in vitro but caused rejection in vivo. Neutrophils were primarily responsible for this rejection. A CD8+ T cell-mediated protective immunity against subsequent challenge with parental tumor cells was also elicited. These results provide evidence for the potential utility of CD95L in tumor eradication and also reveal a proinflammatory function of CD95L.
引用
收藏
页码:165 / 170
页数:5
相关论文
共 50 条
  • [41] Inhibition of CD95 ligand-mediated inflammation
    Seino, K
    Tun, T
    Ohshima, N
    Hamada, H
    Yoshino, K
    Ikeda, S
    Fukunaga, K
    Taniguchi, H
    Takada, Y
    Yuzawa, K
    Otsuka, M
    Todoroki, T
    Fukao, K
    TRANSPLANTATION PROCEEDINGS, 2000, 32 (07) : 2038 - 2039
  • [42] CD95 ligand expression in dedifferentiated breast cancer
    C Moers
    M Müschen
    MW Beckmann
    P Mallmann
    Breast Cancer Research, 3 (Suppl 1)
  • [43] CD95 ligand expression in dedifferentiated breast cancer
    Müschen, M
    Moers, C
    Warskulat, U
    Niederacher, D
    Betz, B
    Even, J
    Lim, A
    Josien, R
    Beckmann, MW
    Häussinger, D
    JOURNAL OF PATHOLOGY, 1999, 189 (03): : 378 - 386
  • [44] Metalloprotease-mediated cleavage of CD95 ligand
    Risso, Vesna
    Thomas, Melissa
    Guevel, Blandine
    Lavigne, Regis
    Com, Emmanuelle
    Martin, Sophie
    Nivet, Manon
    Pineau, Charles
    Negroni, Luc
    Lafont, Elodie
    Chevet, Eric
    Eriksson, Leif A.
    Le Gallo, Matthieu
    FEBS JOURNAL, 2023, 290 (12) : 3145 - 3164
  • [45] CD95 ligand prevents graft rejection.
    Duke, RC
    Moore, JK
    Franzusoff, A
    Bellgrau, D
    FASEB JOURNAL, 1996, 10 (06): : 143 - 143
  • [46] The regulation of CD95 ligand expression and function in CTL
    Li, JH
    Rosen, D
    Ronen, D
    Behrens, CK
    Krammer, PH
    Clark, WR
    Berke, G
    JOURNAL OF IMMUNOLOGY, 1998, 161 (08): : 3943 - 3949
  • [47] Fas ligand (CD95 ligand) controls angiogenesis beneath the retina
    Kaplan, HJ
    Leibole, MA
    Tezel, T
    Ferguson, TA
    NATURE MEDICINE, 1999, 5 (03) : 292 - 297
  • [48] Fas ligand (CD95 ligand) controls angiogenesis beneath the retina
    Henry J. Kaplan
    Marc A. Leibole
    Tongalp Tezel
    Thomas A. Ferguson
    Nature Medicine, 1999, 5 : 292 - 297
  • [49] Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma
    Glick, RD
    Swendeman, SL
    Coffey, DC
    Rifkind, RA
    Marks, PA
    Richon, VM
    La Quaglia, MP
    CANCER RESEARCH, 1999, 59 (17) : 4392 - 4399
  • [50] CD95 (APO-1/FAS) AND THE CD95 LIGAND IN NORMAL AND MALIGNANT B-CELL APOPTOSIS
    DANIEL, PT
    MAPARA, MY
    BOMMERT, K
    BARGOU, RC
    KRAMMER, P
    DORKEN, B
    EXPERIMENTAL HEMATOLOGY, 1995, 23 (08) : 831 - 831